The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2021 | NGS for the detection of mutations in NSCLC
Robin Cornelissen, MD, PhD, Erasmus University Rotterdam, Rotterdam, Netherlands, explains how the introduction of next-generation sequencing (NGS) has enabled to detect mutations in over 500 genes in non-small cell lunger cancer (NSCLC). This information is highly valuable to decide whether a patient should be included in a clinical trial. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.
